LOXL2 and pancreatic adenocarcinoma: However, then, simtuzumab, a function-blocking antibody against LOXL2 with an antidesmoplastic effect in vitro, did not improve the clinical results in patients with KRAS-mutated colorectal or pancreatic adenocarcinoma [430,431,432,433].